CatalystFDA/Bio

SAGIMET BIOSCIENCES INC. (SGMT) DISCUSSES 52-WEEK PHASE 3 DATA AND U.S. PHASE 3 PLANS FOR DENIFANSTAT IN MODERATE TO SEVERE ACNE TRANSCRIPT - SEEKINGALPHA

Phase 3 data and U.S. plans for denifanstat in moderate to severe acne.

What changed

Phase 3 data and U.S. plans for denifanstat in moderate to severe acne.

Why it matters

Phase 3 data and U.S. plans for denifanstat in moderate to severe acne. — impact context not separately stored; see What changed.

Sources